Selective progesterone receptor modulators: Mechanisms of action and possible clinical applications

被引:1
|
作者
Selgrad C. [1 ]
Ortmann O. [1 ]
机构
[1] Klinik und Lehrstuhl für Frauenheilkunde und Geburtshilfe, Universität Regensburg
, Caritas-Krankenhaus St. Josef, Landshuter Str. 65, Regensburg
关键词
Asoprisnil; Contraception; postcoital; Leiomyoma; uterine; Mifepristone; Ulipristal acetate;
D O I
10.1007/s10304-015-0050-2
中图分类号
学科分类号
摘要
Background: Selective progesterone receptor modulators (SPRM) are a group of substances with a multitude of potential applications in the field of gynecological endocrinology. Material and methods: The state of knowledge on the mechanisms of action of SPRMs is summarized based on the currently available literature. In addition, the possible indications are discussed. Results: The effects of progesterone are mediated by progesterone receptors (PR) and SPRMs have agonistic as well as antagonistic effects on the isoforms of PR. The isoforms primarily function as ligand-activated transcription factors. Possible indications are contraception, postcoital contraception, endometriosis therapy and treatment of uterine leiomyomas. Currently approved for clinical use are ulipristal acetate (UPA) and mifepristone (MFP), which can be prescribed as an effective postcoital contraceptive but the exact mechanism of action is not yet fully clarified. Additionally, UPA is a therapy option for premenopausal women with symptomatic uterine leiomyomas. There has been relatively little progress in the development of SPRMs for contraception. So far the amount of data currently available on the indications in the sense of long-term contraception are scarce. Conclusion: The main fields of application of SPRMs are postcoital contraception and preoperative treatment of uterine leiomyomas. Future research efforts concerning the use of SPRMs are currently centered on the field of long-term contraception. Of particular interest is the vaginal ring delivery of UPA. © 2015, Springer-Verlag Berlin Heidelberg.
引用
收藏
页码:44 / 48
页数:4
相关论文
共 50 条
  • [1] Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications
    Chabbert-Buffet, N
    Meduri, G
    Bouchard, P
    Spitz, IM
    HUMAN REPRODUCTION UPDATE, 2005, 11 (03) : 293 - 307
  • [2] Clinical applications of progesterone receptor antagonists and selective progesterone receptor modulators
    Spitz, IM
    ENDOCRINOLOGIST, 2005, 15 (06) : 391 - 400
  • [3] Selective progesterone receptor modulators: an update
    Benagiano, Giuseppe
    Bastianelli, Carlo
    Farris, Manuela
    Brosens, Ivo
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (10) : 1403 - 1415
  • [4] Selective Progesterone Receptor Modulators-Mechanisms and Therapeutic Utility
    Islam, Md Soriful
    Afrin, Sadia
    Jones, Sara Isabel
    Segars, James
    ENDOCRINE REVIEWS, 2020, 41 (05)
  • [5] Selective progesterone receptor modulators
    Whitaker, Lucy H. R.
    Williams, Alistair R. W.
    Critchley, Hilary O. D.
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2014, 26 (04) : 237 - 242
  • [6] Selective progesterone receptor modulators and reproductive health
    Nieman, Lynnette K.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2022, 29 (04) : 406 - 412
  • [7] Selective progesterone receptor modulators. Clinical outlook
    Neulen, J.
    GYNAKOLOGISCHE ENDOKRINOLOGIE, 2008, 6 (04): : 213 - 215
  • [8] Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety
    Bouchard, Philippe
    Chabbert-Buffet, Nathalie
    Fauser, Bart C. J. M.
    FERTILITY AND STERILITY, 2011, 96 (05) : 1175 - 1189
  • [9] Selective progesterone receptor modulators: current applications and perspectives
    Chabbert-Buffet, N.
    Kolanska, K.
    Darai, E.
    Bouchard, P.
    CLIMACTERIC, 2018, 21 (04) : 375 - 379
  • [10] Selective progesterone receptor modulators for the treatment of dysmenorrhea: an update
    Speciale, Anna Rosa
    Ozpinar, Kubra
    Giani, Milo
    Tureli, Dilruba
    Fambrini, Massimiliano
    Vannuccini, Silvia
    Petraglia, Felice
    EXPERT OPINION ON PHARMACOTHERAPY, 2025, 26 (03) : 257 - 264